These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18293994)

  • 1. RCM macrocyclization made practical: an efficient synthesis of HCV protease inhibitor BILN 2061.
    Shu C; Zeng X; Hao MH; Wei X; Yee NK; Busacca CA; Han Z; Farina V; Senanayake CH
    Org Lett; 2008 Mar; 10(6):1303-6. PubMed ID: 18293994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient large-scale synthesis of BILN 2061, a potent HCV protease inhibitor, by a convergent approach based on ring-closing metathesis.
    Yee NK; Farina V; Houpis IN; Haddad N; Frutos RP; Gallou F; Wang XJ; Wei X; Simpson RD; Feng X; Fuchs V; Xu Y; Tan J; Zhang L; Xu J; Smith-Keenan LL; Vitous J; Ridges MD; Spinelli EM; Johnson M; Donsbach K; Nicola T; Brenner M; Winter E; Kreye P; Samstag W
    J Org Chem; 2006 Sep; 71(19):7133-45. PubMed ID: 16958506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
    Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
    Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract]   [Full Text] [Related]  

  • 6. Probing the cation binding modes of macrocyclic HCV protease inhibitor BILN 2061 by multinuclear NMR.
    Busacca CA; Jones PJ; Campbell SJ; Saha AK; Gonnella NC; Senanayake CH
    J Pharm Biomed Anal; 2012 Nov; 70():609-13. PubMed ID: 22766359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convergent synthesis of the quinolone substructure of BILN 2061 via carbonylative Sonogashira coupling/cyclization.
    Haddad N; Tan J; Farina V
    J Org Chem; 2006 Jun; 71(13):5031-4. PubMed ID: 16776542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
    Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
    J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
    Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
    Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.
    Rudd MT; McCauley JA; Romano JJ; Butcher JW; Bush K; McIntyre CJ; Nguyen KT; Gilbert KF; Lyle TA; Holloway MK; Wan BL; Vacca JP; Summa V; Harper S; Rowley M; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; Liverton NJ
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7201-6. PubMed ID: 23021993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of ring-closing metathesis for the synthesis of macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
    Velázquez F; Venkatraman S; Wu W; Blackman M; Prongay A; Girijavallabhan V; Shih NY; Njoroge FG
    Org Lett; 2007 Aug; 9(16):3061-4. PubMed ID: 17608487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virology: fresh assault on hepatitis C.
    Rice CM
    Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
    [No Abstract]   [Full Text] [Related]  

  • 16. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
    Randolph JT; Zhang X; Huang PP; Klein LL; Kurtz KA; Konstantinidis AK; He W; Kati WM; Kempf DJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2745-50. PubMed ID: 18375121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061.
    Stoltz JH; Stern JO; Huang Q; Seidler RW; Pack FD; Knight BL
    Toxicol Pathol; 2011 Apr; 39(3):496-501. PubMed ID: 21441227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrocyclic inhibitors of HCV NS3 protease.
    Venkatraman S; Njoroge FG
    Expert Opin Ther Pat; 2009 Sep; 19(9):1277-303. PubMed ID: 19563268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly convergent and efficient synthesis of a macrocyclic hepatitis C virus protease inhibitor BI 201302.
    Wei X; Shu C; Haddad N; Zeng X; Patel ND; Tan Z; Liu J; Lee H; Shen S; Campbell S; Varsolona RJ; Busacca CA; Hossain A; Yee NK; Senanayake CH
    Org Lett; 2013 Mar; 15(5):1016-9. PubMed ID: 23406520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp²-sp³ Suzuki-Miyaura coupling and ring closing metathesis.
    Li H; Scott JP; Chen CY; Journet M; Belyk K; Balsells J; Kosjek B; Baxter CA; Stewart GW; Wise C; Alam M; Song ZJ; Tan L
    Org Lett; 2015 Mar; 17(6):1533-6. PubMed ID: 25754231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.